BrainsWay (NASDAQ:BWAY - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $16.00 price objective on the stock. HC Wainwright's price target points to a potential upside of 53.11% from the stock's previous close.
BrainsWay Stock Performance
BWAY stock opened at $10.45 on Monday. The company's 50 day moving average price is $9.32 and its 200 day moving average price is $9.76. The firm has a market capitalization of $197.33 million, a price-to-earnings ratio of 104.51 and a beta of 1.32. BrainsWay has a fifty-two week low of $5.67 and a fifty-two week high of $11.79.
BrainsWay (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The company had revenue of $11.54 million for the quarter, compared to the consensus estimate of $11.45 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. Equities analysts forecast that BrainsWay will post 0.08 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. Lazard Asset Management LLC acquired a new stake in shares of BrainsWay during the 4th quarter worth about $44,000. GAMMA Investing LLC increased its stake in BrainsWay by 720.7% in the first quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock valued at $89,000 after purchasing an additional 8,216 shares during the last quarter. Palumbo Wealth Management LLC acquired a new stake in BrainsWay during the first quarter worth approximately $111,000. Trexquant Investment LP purchased a new stake in shares of BrainsWay during the 1st quarter worth approximately $129,000. Finally, Sei Investments Co. purchased a new stake in shares of BrainsWay during the 4th quarter worth approximately $149,000. 30.11% of the stock is owned by institutional investors and hedge funds.
BrainsWay Company Profile
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
